SavedAdd your journal

Journals / Retina-Vitreus / 2006 / Cilt: 14 - Sayı: 2

Intravitreal triamcinolone acetonide applicaitons

İntravitreal triamsinolon asetonid uygulamaları

Tarkan MUMCUOĞLU
A. Hakan DURUKAN
Güngör SOBACI
M. Zeki BAYRAKTAR
Suat KARAGÜL
Pages
161–168
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Intraocular pressure (IOP) elevation, cataract formation, retinal detachment, vitreous hemorrhage and infectious or sterile endophthalmitis are reported complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intravitreal long-acting corticosteroid injection such as triamcinolone acetonide is effective in many ocular chronic disorders.
📊
Key Findings & Data:Intravitreal injections of triamcinolone acetonide have been used widespread as a treatment for intraocular diseases with intraretinal oedema and subfoveal fluid accumulation, such as diffuse diabetic macular oedema, persistent pseudophakic cystoid macular oedema, central retinal vein occlusion, and exudative age related macular degeneration.
💡
Conclusion & Impact:Intraocular pressure (IOP) elevation, cataract formation, retinal detachment, vitreous hemorrhage and infectious or sterile endophthalmitis are reported complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Göz hastalıkları · Triamsinolon asetonit · Eye Diseases

Abstract

Intravitreal long-acting corticosteroid injection such as triamcinolone acetonide is effective in many ocular chronic disorders. Intravitreal injections of triamcinolone acetonide have been used widespread as a treatment for intraocular diseases with intraretinal oedema and subfoveal fluid accumulation, such as diffuse diabetic macular oedema, persistent pseudophakic cystoid macular oedema, central retinal vein occlusion, and exudative age related macular degeneration. Intraocular pressure (IOP) elevation, cataract formation, retinal detachment, vitreous hemorrhage and infectious or sterile endophthalmitis are reported complications.

Özet

Triamsinolon asetonid gibi uzun etkili kortikosteroid enjeksiyonları, birçok oküler kronik hastalıkta etkilidir. İntraretinal ödem ve subfoveal sıvı toplanması ile beraber seyreden diffüz diyabetik maküler ödem, persistan psödofakik kistoid ödem, santral retinal ven tıkanması ve eksüdatif yaşa bağlı maküler dejenerasyon gibi intraoküler hastalıkların tedavisi için intravitreal triamsinolon asetonid (İVTA) enjeksiyonları yaygın olarak kullanılmaktadır. Göz içi basınç (GİB) artışı, katarakt gelişimi, retina dekolmanı, vitreus hemorajisi ve enfeksiyöz veya steril endoftalmi bildirilen komplikasyonlardır.

🔖

Cite This Article

MUMCUOĞLU, T., DURUKAN, A. H., SOBACI, G., BAYRAKTAR, M. Z., KARAGÜL, S. (2006). Intravitreal triamcinolone acetonide applicaitons. Retina-Vitreus, Cilt: 14 - Sayı: 2, 161–168. https://ajindex.com/articles/307791

References (16)

  1. Coles RS, Krohn DL, Breslin H, et al.: Depo-Medrol in treatment of inflammatory diseases of anterior segment of the eye. Am J Ophthalmol. 1962;54:407-411
  2. McCluskey P, Forrester J, Lightman S: Uniocular macular oedema and reduced vision in a patient with uveitis. Clin Experiment Ophthalmol. 2000;8:9-12
  3. Jones JB, Hyler JK, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067
  4. Hernaez-Ortega MC, Soto-Pedre E: A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging. 2004;35:350-351
  5. Nishimura A, Kobayashi A, Segawa Y, et al.: Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina. 2003;23:777-779
  6. Gilles MC, Simpson JM, Billson FA, et al.: Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol. 2004;122:336-340
  7. Jonas JB, Degenring R, Kreissing I, et al.: Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol. 2004;138:1054-1055
  8. Mason JO, Somaiya MD, Singh RJ: Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004;24:900-904
  9. Beer PM, Bakri SJ, Singh RJ, et al.: Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686
  10. Jonas JB: Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;137:560-562
  11. Inoue M, Takeda K, Morita K, et al.: Vitreous concentration of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138:1046-1048
  12. Degenring RF, Jonas JB: Serum levels of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol. 2004;137:1142-1143
  13. Martidis A, Duker JS, Greenberg PB, et al.: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927
  14. Greenberg PB, Martidis A, Rogers AH, et al.: Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2002;86:247-248
  15. Antcliff RJ, Spalton DJ, Stanfort MR, et al.: Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772
  16. Conway MD, Canakis C, Livir-Rallato